- Samsung Biologics reported an impressive operating profit of 486.69 billion won in the first quarter of 2025.
- This operating profit figure is significantly higher than last year’s 221.30 billion won and exceeded the market estimate of 347.19 billion won.
- The company’s net profit stood at 375.55 billion won, surpassing last year’s 179.36 billion won and exceeding the forecasted 297.47 billion won.
- Samsung Biologics achieved a 37% year-over-year increase in sales, totaling 1.30 trillion won, which is higher than the estimated 1.21 trillion won.
- Current market analyst ratings for Samsung Biologics include 31 buy recommendations, no holds, and 1 sell recommendation.
Samsung Biologics on Smartkarma
Analyst coverage of Samsung Biologics on Smartkarma has been positive, with a bullish sentiment reflected in recent reports. In one analysis by Sanghyun Park titled “4 Key Movers in TIGER Top 10 in June Reshuffle“, the post highlighted Samsung Biologics as a strong contender following a market reshuffle. The report suggested a strategy of trimming the holding window on rebalance day and implementing a long-short strategy based on historical trends.
Another report by analyst Tina Banerjee, titled “Samsung Biologics (207940 KS): Record High Revenue in 2024; Accelerated Growth Expected in 2025“, emphasized the company’s exceeding revenue expectations in 2024 and anticipated accelerated growth in 2025. With plans to increase capacity through Plant 5 and expectations of 20-25% revenue growth in 2025, Samsung Biologics appears well-positioned for resilience and further success within the industry.
A look at Samsung Biologics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts have assessed Samsung Biologics with a range of Smart Scores to gauge its long-term prospects. The company shows strong potential for growth with a high score of 5 in that area. Additionally, Samsung Biologics received solid ratings for resilience and momentum, scoring 4 in both categories. This indicates that the company is well-positioned to weather economic uncertainties and maintain positive performance trends over time. On the other hand, its value and dividend scores were somewhat lower at 2 and 1, respectively.
Samsung Biologics Co., Ltd., known for manufacturing bio-healthcare products, has a promising long-term outlook with its notable strengths in growth, resilience, and momentum. With a focus on developing and distributing biopharmaceutical products, the company’s strategic positioning in the market aligns with its strong growth potential. While its value and dividend scores are comparatively lower, Samsung Biologics’ emphasis on innovation and expansion could drive favorable outcomes in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
